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Background: BRCA1/2 mutation carriers are recommended to undergo risk-reducing salpingo-oophorectomy (RRSO) at 35
to 45 years of age. RRSO substantially decreases ovarian cancer risk, but at the cost of immediate menopause. Knowledge about
the potential adverse effects of premenopausal RRSO, such as increased risk of cardiovascular disease, osteoporosis, cognitive
dysfunction, and reduced health-related quality of life (HRQoL), is limited.
Objective: The aim of this study is to assess the long-term health effects of premenopausal RRSO on cardiovascular disease,
bone health, cognitive functioning, urological complaints, sexual functioning, and HRQoL in women with high familial risk of
breast or ovarian cancer.
Methods: We will conduct a multicenter cross-sectional study with prospective follow-up, nested in a nationwide cohort of
women at high familial risk of breast or ovarian cancer. A total of 500 women who have undergone RRSO before 45 years of
age, with a follow-up period of at least 10 years, will be compared with 250 women (frequency matched on current age) who
have not undergone RRSO or who have undergone RRSO at over 55 years of age. Participants will complete an online questionnaire
on lifestyle, medical history, cardiovascular risk factors, osteoporosis, cognitive function, urological complaints, and HRQoL. A
full cardiovascular assessment and assessment of bone mineral density will be performed. Blood samples will be obtained for
marker analysis. Cognitive functioning will be assessed objectively with an online neuropsychological test battery.
Results: This study was approved by the institutional review board in July 2018. In February 2019, we included our first
participant. As of November 2020, we had enrolled 364 participants in our study.
Conclusions: Knowledge from this study will contribute to counseling women with a high familial risk of breast/ovarian cancer
about the long-term health effects of premenopausal RRSO. The results can also be used to offer health recommendations after
RRSO.
Trial Registration: ClinicalTrials.gov NCT03835793; https://clinicaltrials.gov/ct2/show/NCT03835793.
International Registered Report Identifier (IRRID): DERR1-10.2196/24414
(JMIR Res Protoc 2021;10(1):e24414) doi: 10.2196/24414
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Introduction
Background
Female BRCA1 germline mutation carriers have a cumulative
risk of 44% to develop ovarian cancer before the age of 80 years.
For BRCA2 mutation carriers, this cumulative risk is 17% [1].
In the absence of an effective screening method for ovarian
cancer, risk-reducing salpingo-oophorectomy (RRSO) is advised
at an age when there is a high risk of developing ovarian cancer
(before the age of 35-40 years for BRCA1 mutation carriers and
at the age of 40-45 years for BRCA2 mutation carriers) provided
that the woman no longer has a wish to have children [2,3].
During this procedure, both ovaries and fallopian tubes are
removed. Since 2009, the uptake of RRSO in BRCA1/2 mutation
carriers in the Netherlands has increased greatly from 81% to
98% currently [4-6]. While RRSO at the recommended age
decreases the risk of ovarian cancer by around 96% [7,8], it also
initiates premature surgical menopause owing to a sudden drop
in the levels of ovarian hormones. Whether RRSO also reduces
the risk of breast cancer is currently debated. Various early
studies have reported a risk reduction of 50%, but this is a
substantial overestimation owing to bias [8-11].
The relationship between early menopause (either surgically
induced or due to premature ovarian insufficiency [POI]) and
noncancer health outcomes, including cardiovascular disease
(CVD), osteoporosis, cognition, and health-related quality of
life (HRQoL), has been examined previously. However, most
of the published studies had a limited follow-up (median <5
years), which is too short to establish an association with
long-term health effects [12-15]. Additionally, hormone
replacement therapy (HRT) use, cancer treatment, and lifestyle
may alter the potential association of RRSO with noncancer
health outcomes. BRCA1/2 mutation carriers may have been
treated for breast cancer, which can be cardiotoxic and
potentially have a negative impact on the brain [16-19]. Lastly,
women with a high familial risk of breast/ovarian cancer may
have a healthier lifestyle than age-matched women without a
family history of breast cancer, rendering translation of results
of previous research on early menopause to this specific
population difficult [20].
Early Menopause and Cardiovascular Risk
Before the age of 50 years, female sex hormones, such as
estrogen and progesterone, are likely to protect women against
CVD as they have atheroprotective properties [21,22]. Previous
studies have shown that women with POI are at higher risk of
developing CVD and that earlier age at menopause is associated
with a higher cardiovascular mortality rate [23-26]. Additionally,
a higher risk of CVD has been observed after surgical
menopause compared with natural menopause [27]. However,
age at surgical menopause was often not specified or surgery
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was performed at later ages than the recommended young ages
for RRSO in BRCA1/2 mutation carriers. Thus, information
about the cardiovascular risk of early surgical menopause is
still limited [27-29]. Furthermore, it is possible that early loss
of ovarian hormones is not the cause of the higher
cardiovascular disease risk in women with POI. The reverse
causality hypothesis postulates that POI is the result of
accelerated vascular aging, which would also explain a statistical
(noncausal) association between earlier natural menopause and
increased CVD risk [30]. If this is true, no elevated CVD risk
would be expected in women with early surgical menopause
due to RRSO.
Early Menopause and Bone Health
Reproductive hormones play a role in maintaining bone health.
Estrogen suppresses bone resorption and stimulates bone
formation [31]. Postmenopausal women aged 50 to 55 years
have a higher incidence of hip fractures than age-matched
premenopausal women, and among postmenopausal women,
the incidence of hip fractures rises with age [32]. However, data
on the long-term effect of early (surgical or natural) menopause
on bone health are limited owing to short follow-up periods.
Early Menopause and Cognition
The neuroprotective effects of estrogens, progestogens, and
androgens have been described in several studies [33]. Rocca
et al observed that women who underwent premenopausal
oophorectomy (before 56 years of age) for benign reasons had
a higher risk of cognitive impairment than age-matched women
without oophorectomy [34]. There was a trend for more severe
cognitive impairment with younger age at oophorectomy for
both unilateral and bilateral oophorectomies. However,
information on BRCA1/2 mutation carriership was not provided
[34]. Additionally, Bove et al observed a faster decline in global
cognition in women with an earlier age at surgical menopause
[14]. Thus, while there are some data on the effect of surgical
menopause on cognition, research on BRCA1/2 mutation carriers
is limited.
Early Menopause and HRQoL
RRSO may have an important impact on HRQoL, including
generic issues, such as physical, role, and emotional functioning,
as well as cancer-related anxiety, sexual functioning, and
menopause-specific symptoms [12,35,36]. However, it is not
known whether these effects persist over time. A recent study
with a mean follow-up of 7.9 years after RRSO found that
moderate to severe menopausal complaints were still present
in almost 70% of women who underwent premenopausal RRSO,
without any improvement over time [37]. The magnitude of the
effect of RRSO on sexual functioning and endocrine symptoms
is modulated by HRT use [38,39]. However, HRT use is
contraindicated for BRCA1/2 mutation carriers with a history
of breast cancer.
The number of postmenopausal years is associated with an
increased prevalence of vulvovaginal atrophy [40]. Atrophy of
the urethral epithelium may lead to urinary incontinence. To
our knowledge, no research has been conducted on the
association between early surgical menopause and urinary
incontinence, although this generally has a severe impact on
sexual functioniƒng and quality of life [41,42].
Figure 1 provides a schematic overview of the effects of a
decrease in estrogen levels due to menopause on various organ
systems.
Figure 1. Overview of the effects of reduced estrogen levels on various organ systems.
A recent Cochrane systematic review on the benefits and harms
of RRSO in women with a BRCA1/2 mutation stated that no
conclusions can be drawn regarding bone fracture incidence
and HRQoL, and that further research is needed. CVD and
cognition were not included as outcomes in this review, probably
because of the paucity of studies [43]. Therefore, the aim of the
HARMOny study (Health After eaRly Menopause due to
Oophorectomy) is to investigate the long-term health effects of
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RRSO. We will conduct a cross-sectional study with prospective
follow-up nested in a large Dutch cohort. We hypothesize that
women with surgically induced premature menopause are at
higher risk of subclinical CVD, compromised bone health and
osteoporosis, reduced HRQoL, and impaired cognitive
functioning, compared to age-matched women with natural
menopause after the age of 50 years. Depending on the results,
this may lead to active surveillance of the above health problems




The primary aim of our study is to assess the long-term health
effects of RRSO on subclinical CVD, bone mineral density
(BMD), and cognitive functioning in women at increased
familial risk of breast or ovarian cancer mainly due to a
BRCA1/2 mutation. Our secondary study aims are to assess
overall HRQoL, endocrine symptoms, such as hot flashes and
night sweats, sexual functioning, urogenital problems, and the
prevalence of cardiovascular risk factors.
Recruitment
We will include 500 women who have undergone RRSO before
the age of 45 years, with a follow-up period of at least 10 years
(the early RRSO group). We will compare them with 250
women from the same cohort (frequency matched on current
age) who have not undergone preventive RRSO or have
undergone RRSO at the age of 55 years or above (the
late/non-RRSO group). The exclusion criteria are a metastatic
disease; a serious physical comorbidity or psychiatric disorder;
a language barrier; a metal cardiac valve; a bare metal coronary
stent, since the reflection of the stent would interfere with the
computed tomography scan; and natural POI before the age of
40 years. A history of nonovarian cancer, including breast
cancer, is not a reason to be excluded.
Eligible women who are alive will be invited for a clinic visit
and questionnaire survey that will assess CVD status, BMD,
cognitive functioning, and HRQoL. For eligible women who
have died, we will collect information on the causes of death
to examine selection bias.
Participants will be selected from the dynamic nationwide
HEBON study cohort, a national collaboration on HEreditary
Breast and Ovarian cancer in the Netherlands, with women
tested for BRCA1/2 germline mutations included since 1997 by
all eight Dutch University Medical Centers (UMCs) and the
Netherlands Cancer Institute (NKI). The cohort currently
consists of over 3600 proven female BRCA1/2 germline
mutation carriers. Participants have given informed consent for
linkage with the Netherlands Cancer Registry and the Dutch
Nationwide Pathology Database (PALGA), which can provide
information on all prophylactic mastectomies and
salpingo-oophorectomies performed in the Netherlands since
1991. This provides us with nearly complete information on the
occurrence of RRSO. Data on lifestyle, family history,
reproductive factors, and hormone use have been collected from
HEBON participants through questionnaires [44].
Figure 2 provides a schematic overview of the patient selection
and eligibility criteria of our study population.
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Figure 2. Schematic overview of the eligibility criteria.
Participants will be asked to complete an online questionnaire
and an online cognitive assessment, and they will be asked to
visit the outpatient clinic for a cardiovascular and bone health
assessment. We will assess several surrogate endpoints of
cardiovascular health, that is, coronary artery calcium (CAC)
score (CAC scoring), pulse wave velocity (PWV), advanced
glycation end products (AGEs), anthropometric measurements,
and blood sampling. We will determine nonfasting blood levels
of lipids, glucose, HbA1c, high-sensitivity cardiac troponin, and
high‐sensitivity C‐reactive protein. BMD is assessed by a
dual-energy X-ray absorptiometry (DXA) scan and laboratory
blood sampling, and cognitive functioning is assessed by the
Amsterdam cognition scan (ACS).
The online questionnaire is divided into the following several
topics: general cardiovascular history, family history of CVD,
traditional CVD risk factors (ie, diabetes, hypertension, and
cholesterol), lifestyle (ie, smoking, alcohol use, and physical
activity), female-specific risk factors (hypertensive pregnancy
complications, gestational diabetes, contraceptives use, and
HRT use, ie, type, duration, and timing), history of fractures,
calcium intake, vitamin D supplement use, glucocorticoid use,
family history of osteoporosis/fractures, history of inflammatory
diseases (rheumatoid disease and thyroid disorders), and
perceived cognitive problems. We will assess generic HRQoL
with the SF-36 health survey [45,46] and the body image items
of the European Organization for Research and Treatment of
Cancer (EORTC) QLQ-BR23 [47,48]. Cancer worries will be
measured with the eight items adapted from Lerman et al
[49-51]. To assess menopausal symptoms, we will employ the
18-item Functional Assessment of Cancer Therapy-Endocrine
Subscale (FACT-ES) and the Hot Flush Rating Scale (HFRS)
[52,53]. To assess urogenital problems, the Urogenital Distress
Inventory (UDI-6) and Incontinence Impact Questionnaire
(IIQ-7) [54] will be used. The Sexual Activity Questionnaire
(SAQ) [55] will be used to assess sexual functioning. For
patients with a breast cancer history, either before or after
RRSO, we will collect information on radiotherapy (yes/no and
radiation fields), chemotherapy and immunotherapy regimens,
and endocrine treatment from medical records.
Measurements of the CAC score as calculated by coronary
calcium scoring will be performed according to standardized
local protocols at the various UMCs using the Agatston score
(AS) and the Multi-Ethnic Study of Atherosclerosis (MESA)
coronary heart disease risk score calculator [56,57]. A
disadvantage of CAC scoring might be the use of ionizing
radiation. However, the radiation dose in the CAC protocol is
as low as 1 mSv, which is not expected to be harmful [58]. All
patients in our study are aged 55 years or above; thus, the
radiation-induced risk of breast cancer from CAC scoring will
be negligible with the current protocol [59,60].
The PWV will be assessed with an ambulatory arteriograph
(TensioMed Kft) by the research physician. The arteriograph
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uses an oscillometric occlusive method, with an upper arm cuff
to measure the time interval between the peak of the first systolic
wave and the peak of the reflected systolic wave (return time).
The device has been validated in numerous studies [61-65].
With aging, the end products of nonenzymatic modification of
proteins, lipids, and nucleic acids (AGEs) accumulate
endogenously in the serum and tissues. Levels of AGEs in the
skin are measured noninvasively by standardized
autofluorescence and can predict future cardiovascular events
[66,67]. Skin autofluorescence is a quick and noninvasive
surrogate marker of tissue accumulation of AGEs [68-70]. AGEs
will be measured using the AGE Reader (DiagnOptics
Technologies BV; software V 2.3.0.7) on the forearm.
Bone health will be assessed by a DXA scan, a vertebral fracture
assessment, and blood levels of bone turnover markers (BTMs)
for osteoclast and osteoblast activity (beta-carboxy-terminal
collagen crosslinks [β-CTX] and N-terminal procollagen type
1 [P1NP]). For logistic reasons, it is not possible to get fasting
blood samples for every woman. Since β-CTX values are only
valid in fasting blood samples, we will assess this BTM only
in those women for whom we have fasting blood samples. P1NP
will be measured in all samples.
Lastly, women will receive an invitation to fill out the online
ACS, which has recently been developed and validated [71].
The ACS is an easy to use tool to obtain online measures of
various cognitive abilities [72]. The online test battery is based
on seven traditional neuropsychological tests and covers the
following domains: verbal memory, attention, executive
functioning, information processing speed, and motor
functioning.
Table 1 provides an overview of the tests that will be performed
[58,61-63,66,67,69,71-77]. Table 2 provides an overview of
the questionnaires used [45-50,52-55].
We will examine the effect of age at RRSO on the risk of breast
cancer, contralateral breast cancer, and ovarian cancer, as well
as associations between RRSO and the prognosis of subsequent
breast cancer and ovarian cancer. Additionally, after completion
of the cross-sectional study, we will perform longitudinal
follow-up every 4 to 5 years to evaluate incidence rates of
outcomes of major interest, such as ischemic heart disease, and
evaluate changes in outcomes (CAC, PWV, BMD, and cognitive
functioning as assessed by the ACS) over time between the
early RRSO group and the late/non-RRSO group. Moreover,
with the anticipated prospective follow-up of our study
population, we will look at mortality of cardiovascular disease.
All data, including blood and DNA samples, will be stored for
30 years to enable prospective longitudinal follow-up of the
study population on the long-term health effects of RRSO. The
stored blood samples will allow for future international studies,
for example, those on the modifying effects of genetic factors,
such as single nucleotide polymorphisms, on the outcomes of
interest, and the novel cardiovascular markers or BTMs for
these outcomes. All blood samples will be frozen and stored at
−80°C at the NKI.
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Table 1. Overview of the tests that will be performed.
JustificationOutcome variablesData collection method and
references
Aim of the test
Measurements of the CAC score as calculated by coronary
calcium scoring will be performed according to standard-
ized local protocols at the various University Medical
Centers using the Agatston score (AS) and the MESAa
coronary heart disease risk score calculator.




The PWV will be assessed with an ambulatory arteriograph
(TensioMed Kft) by the research physician. The arterio-
graph uses an oscillometric occlusive method, with an upper
arm cuff to measure the time interval between the peak of
the first systolic wave and the peak of the reflected systolic
wave (return time).




With aging, the end products of nonenzymatic modification
of proteins, lipids, and nucleic acids (AGEs) accumulate
endogenously in the serum and tissues. Levels of AGEs in
the skin are measured noninvasively by standardized aut-
ofluorescence and can predict future cardiovascular events.
AGEs will be measured using the AGE Reader (DiagnOp-
tics Technologies BV; software V 2.3.0.7).








• Blood pressure in mmHg
• Pulse frequency per minute
• Waist (in cm)/hip (in cm) ratio
• BMI in kg/m2
Predictors of future cardiovascular events.Nonfasting blood levels for lipids
(total cholesterol, high-density
lipoprotein cholesterol, low-density
lipoprotein cholesterol, and triglyc-
erides), glucose, HbA1c, high-sensitiv-




The DXA scan is most widely used in clinical practice to
screen for osteoporosis and is regarded as the “gold stan-
dard.”
Dual-energy X-ray absorp-
tiometry (DXA) scan of the
lumbar spine and hip
Bone health • BMDb values in g/cm2
• T and Z scores
• Presence of osteopenia (defined
as T-scores of −1 to −2.5)
• Presence of osteoporosis (de-
fined as T-scores of ≥−2.5)




Bone health • Vertebral height reduction in
percentage
• Presence of clinical and nonclin-
ical vertebral fractures
Bone turnover markers (BTMs) for osteoclast and os-
teoblast activity (β-CTX and P1NP). For logistic reasons,
it is not possible to get fasting blood samples for every
woman. Since β-CTX values are only valid in fasting blood
samples, we will assess this BTM only in those women for
whom we have fasting blood samples. P1NP will be mea-
sured in all samples.
Laboratory blood sampling
[77]
Bone health • Bone formation by P1NPc, mean
value in ng/mL
• Bone resorption by β-CTXd,
mean value in pg/mL
• Level of 25-hydroxyvitamin D
in the serum in nmol/L
The ACS is an easy-to-use tool to obtain online measures
of various cognitive abilities [72]. The online test battery








• Information processing speed
• Motor functioning
aMESA: Multi-Ethnic Study of Atherosclerosis.
bBMD: bone mineral density.
cP1NP: N-terminal procollagen type 1.
dβ-CTX: beta-carboxy-terminal collagen crosslinks.
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Table 2. Overview of the questionnaires.
TopicsAim of the questionnaire
General cardiovascular history
Cardiovascular disease risk factors (ie, obesity, diabetes, hypertension, and dyslipidemia)
Lifestyle (ie, smoking, alcohol use, and physical activity)
Female-specific risk factors (ie, hypertensive pregnancy complications, gestational diabetes, contraceptive use,
and hormone replacement therapy use)






Family history of osteoporosis/fractures
History of inflammatory diseases (ie, rheumatoid disease and thyroid disorders)
Bone health
Perceived cognitive problemsCognitive health
SF-36 health survey
Body image items of the European Organization for Research and Treatment of Cancer (EORTC) QLQ-BR23
Cancer worries; eight items adapted from Lerman et al
The 18-item Functional Assessment of Cancer Therapy-Endocrine Subscale (FACT-ES) measure of endocrine
symptoms
Hot Flush Rating Scale (HFRS)
Urogenital Distress Inventory (UDI-6)
Incontinence Impact Questionnaire (IIQ-7)
Sexual Activity Questionnaire (SAQ)
Health-related quality of life
[45-50,52-55]
Statistical Analysis
We will analyze differences in the cardiovascular risk profile,
BMD, and neurocognitive functioning between the early RRSO
group and the late/non-RRSO group using multivariable linear
regression analyses and logistic regression analyses with
clinically relevant cutoff points for the outcomes of interest.
The analyses will be adjusted for confounders, including
lifestyle, reproductive factors, and medication use, where
applicable. For the analysis of patient-reported outcomes, such
as HRQoL, sexual functioning, and menopausal symptoms, we
will use mixed effect models.
We expect approximately 40% of the women to have a breast
cancer history and will perform the analyses separately in
women with and those without a breast cancer history, as breast
cancer treatment may affect outcomes. Additional subgroup
analyses will be performed according to HRT use (yes/no),
BRCA1/2 mutation status, age at RRSO (<40 years/≥40 years),
and time since RRSO (10-15 years/>15 years).
Sample Size Calculation
We based our sample size calculations for cardiovascular status
on subclinical atherosclerosis by assessing the differences in
the CAC score between women in the early RRSO group and
women in the late/non-RRSO group. We chose a clinically
relevant cutoff for the CAC score of 100 Agatston units (AU).
According to the MESA trial, 10% of subjects between 55 and
65 years of age exceed this value [78]. For sample size
estimation, we hypothesized that 20% of the early RRSO group
exceeds this value of 100 AU. In logistic regression with an
elevated CAC score (>100) as the outcome and with 250 women
in the late/non-RRSO group and 500 women in the early RRSO
group, we have 80% power to detect an odds ratio of 1.9 at an
α value of 5%.
With 750 women in our study, we will be able to detect a
difference of 0.07 g/cm2 in BMD between the early RRSO and
late/non-RRSO groups, as observed between women with
premature and normal menopause and assuming an SD of 0.15
[79]. Statistical power for analysis of cognitive functioning is
based on a previous neuropsychological study on the effects of
oophorectomy on cognitive impairment and dementia [34]. This
study reports relevant differences in 427 women with bilateral
oophorectomy before the age of 49 years, compared to
age-matched women without oophorectomy, with a median
follow‐up of 25 years. As our neurocognitive tests are more
sensitive than the tests screening for dementia, we expect to be
able to detect smaller differences in cognitive functioning and
distinguish between different cognitive domains, and with 750
participants, we have 90% power to detect an effect size of 0.25
with a P value set at .05 (two tailed). To detect a relevant
difference between groups for the various HRQoL measures,
we will use a half SD (an effect size of 0.5) to define clinically
relevant group differences (over time). This requires about 67
patients per group. The available sample will be more than
adequate to conduct subgroup analyses as well.
Results
This study was funded by the Dutch Cancer Society in 2016.
The Institutional Review Board of the Netherlands Cancer
Institute approved this nationwide multicenter study in July
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2018, and local approval from the participating sites followed
in the months thereafter.
This study will be conducted according to the standards of Good
Clinical Practice, in agreement with the principles of the
Declaration of Helsinki and with the Dutch law as stated in the
Medical Research Involving Human Subjects Act (WMO). The
study has been approved in writing by the Medical Ethics
Committee of the Antoni van Leeuwenhoek/Netherlands Cancer
Institute (AVL/NKI) to be conducted in all nine University
Medical Centers and the Antoni van Leeuwenhoek and has been
registered at “CCMO Toetsingonline” from the Dutch Central
Committee on Research involving Human Subjects (file number
NL63554.031.17) and on ClinicalTrials.gov (NCT03835793).
Written informed consent will be collected from the participants.
In February 2019, we included our first participant, and as of
November 2020, we had enrolled 364 participants in our study.
Of these 364 participants, 228 are in the early RRSO group and
136 are in the late/non-RRSO group. Recruitment of participants
is currently ongoing. Results will be disseminated through
peer-reviewed publications and will be incorporated in follow-up
guidelines.
Discussion
To our knowledge, this study is the first to assess the long-term
noncancer health outcomes of early surgical menopause in
women with a high familial risk of ovarian cancer, focusing on
CVD, bone health, cognition, and HRQoL. The issue is
important as RRSO at the age of 35-45 years is an increasingly
common procedure in BRCA1/2 mutation carriers, with an
estimated uptake in the Netherlands of 81% to 99% [4,5]. We
have designed a nationwide, multicenter, multidisciplinary,
cross-sectional study with prospective follow-up, comparing
500 women who have undergone RRSO before 45 years of age
(more than 10 years of follow-up) with 250 women who have
undergone RRSO after 55 years of age or who have not
undergone RRSO. The unique features of our study are near
complete information on the occurrence of RRSO in the cohort
and long-term follow-up of all cohort members, allowing the
selection of the eligible population for this study at least 10
years after RRSO. Our study is nested in a cohort of women
with a high familial risk of breast and ovarian cancer, which
will allow us to evaluate potential differences in disease risks
between our study population and the entire cohort in order to
quantify any survivorship and selection bias and to adequately
interpret the magnitude of our effect sizes.
At present, it is still unclear whether early surgical menopause
can be considered as a clinically relevant risk factor for CVD.
During normal menopausal transition, CVD risk increases
[23,26,78,80]. Women with an early natural menopause (<40
years) are at higher risk of developing CVD, and they have a
higher CVD mortality than age-matched peers [23-26].
However, it has been debated whether this association is causal,
and it has been speculated that this might also be explained by
early vascular aging predisposing to both POI and cardiovascular
disease [30,81]. If this is true, an artificial early menopause
might not be associated with increased CVD risk. In support of
this, a recent study by Krul et al showed that cancer
treatment–induced POI did not affect CVD risk [82]. This
renders it even more interesting to investigate CVD risk in
women with surgically induced early menopause. To date, this
has been addressed in only a few studies, with inconsistent
results and with a median follow-up of at the most 5 years,
which is too short considering potential delayed effects of
estrogen deprivation and the long life expectancy of these
women. Furthermore, previous studies vary with respect to HRT
use and age at surgery [27-29].
The association between early surgical menopause and long-term
bone health has also been rarely examined. Studies were
inconclusive regarding decreased BMD and increased fracture
risk, and whether these risks remain increased over time [83,84].
In addition, the effect of early RRSO on cognition has not yet
been examined. However, both unilateral and bilateral
oophorectomies at later ages have been associated with cognitive
impairment and dementia, suggesting neuroprotective effects
of estrogen on the brain. These effects appear to be age
dependent [34,85].
After menopause, women more often report sexual and
urogenital problems, such as urinary incontinence, recurrent
urinary tract infections, impaired libido, and dyspareunia, which
interfere with HRQoL. Women with POI experience these
problems even more [86,87]. We do not know if these results
can be generalized to surgical early menopause. Studies on
long-term HRQoL after RRSO are limited and highly biased
by HRT use.
One of the major strengths of our study is that it will be the first
to examine the health effects of premenopausal RRSO at less
than 45 years with a follow-up of over 10 years compared to
controls with natural menopause. Additionally, owing to the
large number of participants, we will have sufficient power for
subgroup analyses. A limitation of our study could be survivor
bias. Owing to the inclusion criterion of at least 10 years of
follow-up, patients may already have died of relevant study
outcomes before study inclusion. However, as we conduct the
cross-sectional study within a well-characterized cohort, we can
assess the extent of such bias by collecting cause of death
information for potentially eligible but already deceased women.
This initial cross-sectional study will provide prevalence rates
of noncancer outcomes. Therefore, we will follow the study
cohort prospectively to obtain incidence rates of outcomes of
interest and evaluate changes in outcomes over time.
To summarize, the current literature lacks information on
long-term noncancer outcomes in women at increased risk of
breast/ovarian cancer who have undergone early oophorectomy.
With this study, we will be able to provide insights into the
prevalence and severity of CVD, osteoporosis, cognitive
impairment, and HRQoL effects after RRSO. This knowledge
will yield evidence-based information for women and for health
care providers about the long-term effects of early RRSO. The
results can be incorporated in decision-support tools about
risk-reducing surgeries in BRCA1/2 mutation carriers
considering RRSO and can be used to offer individualized
counseling about additional screening and interventions for
noncancer diseases or complaints after RRSO.
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